MarketsandMarkets: U.S. Biopharmaceuticals Market Worth $144 Billion by 2016By Marketsandmarkets, PRNE
Wednesday, December 1, 2010
DALLAS, December 2, 2010 - BIOPHARMA analyzes the U.S. Biopharmaceuticals Market and its growth
factors, with special emphasis on the top companies in the field and their
product pipeline. The report also analyses the current trends and focus of
the U.S. biopharmaceutical market and the challenges faced by the industry.
It also provides profiles of the major companies participating in the United
Browse market data tables and in-depth TOC on BIOPHARMA
Early buyers will receive 10% customization of reports.
The U.S. biopharmaceuticals market is expected to increase to $144
billion by 2016. This growth is expected as a result of the launch of new
products, approval of new indications for existing therapies and drugs, and
increase in population aged 65 years and above. From 2009 to 2016 the U.S.
market revenues are forecasted to grow at a compound annual growth rate
(CAGR) of 11.2%.
This research report analyzes the U.S. biopharmaceuticals market and its
growth factors, with special emphasis on top companies in the field and their
product pipeline. While it looks at the overall market size and presents
forecast till 2016.
A key focus of the report is the increasing role of biopharmaceutical
products. The growing interest in biotechnology development has led to the
metamorphosis of the pharmaceutical industry, resulting in the subset
industry of biopharmaceuticals. The big players in the pharma industry,
including Pfizer, Merck, and Novartis, have been the first few to reap the
benefits of investing in biotechnology through both organic as well as
inorganic growth mechanisms.
Market forecasts include the biopharmaceuticals currently in the market
as well as those projected to enter the market by the end of the forecast
period in 2016. Market challenges, drivers, and restraints have also been
identified and assessed. Selected late stage pipeline analysis is also
This report analyzes the biopharmaceutical industry's products, features,
companies, market size and potential and patent portfolios. The impact of the
Medicare and Medicaid policies and individual plan behaviors on the
biopharmaceutical industry is also discussed.
- To define and measure the biopharmaceutical market in the U.S. - To identify the major drivers, restraints, and opportunities in the biopharmaceutical market. - To identify and analyze comprehensively the biopharmaceutical market structure with respect to the factors influencing market growth and industry-specific challenges. - To analyze the trends and provide the forecasts for the biopharmaceutical market and its segments with respect to different geographies. - To identify the major stakeholders in the biopharmaceutical market and draw a competitive landscape. - To understand the regulatory framework, patient safety and pricing issues of the biopharmaceutical market.
Scope of the report
This section discusses the market definition of U.S. biopharmaceutical
market. This section also discusses the way market is segmented and the
methodology as well as the assumptions considered for forecasting the
revenues for the all the individual product/drug class segments.
This research service covers biopharmaceuticals and their impact on the
U.S. healthcare market.
Products included in this study by their market segmentation:
- Gene and Cell therapies, including "Antisense Therapies" - Cytokines - PEH: Proteins, Enzymes, and Hormones - Monoclonal Antibodies - Vaccines - Others: Blood and Allergenic components and others.
Products not included:
- Biosurgical products like tissue grafts and sealants - Biologics used for diagnostic purposes - Bionanotechnology drugs
This section discusses the current trends and focus of the U.S.
biopharmaceutical market and the challenges faced by the industry. Other
sections include market analysis, patent analysis and competitive landscape.
This section provides the company profiles of major companies
participating in the U.S. biopharmaceutical market. Company profiles include
a brief overview of the company, primary business, strategies followed and
Analyst Briefing Presentation on U.S. Biopharmaceutical Market - Trends,
Forecast, Competition & Strategic Analysis (2009 - 2016) to be held on 14 Dec
The CMF practice at MarketsandMarkets is pleased to announce its Analyst
Briefing Presentation on U.S. Biopharmaceutical Market - Trends, Forecast,
Competition & Strategic Analysis (2009 - 2016) to be held on 14 Dec 2010. The
briefing will cover an analysis of trends and current focus of the U.S.
biopharmaceutical market and the challenges faced by the industry. The impact
of biopharmaceuticals on the U.S. healthcare market will also be discussed
during the briefing.
To register for this briefing, please click here
MarketsandMarkets (M&M) is a global market research and consulting
company based in the U.S. We publish strategically analyzed market research
reports and serve as a business intelligence partner to Fortune 500 companies
across the world. MarketsandMarkets also provides multi-client reports,
company profiles, databases, and custom research services.
M&M covers thirteen industry verticals, including advanced materials,
automotive and transportation, banking and financial services, biotechnology,
chemicals, consumer goods energy and power, food and beverages, industrial
automation, medical devices, pharmaceuticals, semiconductor and electronics,
and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by
providing apt business insight with our huge market intelligence repository.
To know more about us and our reports, please visit our website
Contact: Ms. Sunita 7557 Rambler Road Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004 Email: firstname.lastname@example.org www.marketsandmarkets.com marketsandmarkets.wordpress.com/ marketsandmarkets.blogspot.com/
Ms. Sunita, 7557 Rambler Road, Suite 727, Dallas, TX 75231, Tel: +1-888-989-8004
Tags: Dallas, December 2, MarketsandMarkets, texas